Journal Article
. 2007 Feb;109(6).
doi: 10.1002/cncr.22506.

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

Gary H Lyman 1 Leon E Cosler  Nicole M Kuderer  John Hornberger  
Affiliations
  • PMID: 17311307
  •     57 citations

Abstract

Background: The prognostic accuracy for distant recurrence-free survival using a 21-gene reverse-transcriptase polymerase chain reaction (RT-PCR) assay underwent validation in 668 lymph node-negative, estrogen receptor-positive women with early-stage breast cancer receiving tamoxifen on National Surgical Adjuvant Breast Program (NSABP) B-14. The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14.

Methods: Patients were classified as high (recurrence score [RS] >or= 31), intermediate (RS 18-30), or low (RS < 18) risk for distant recurrence at 10 years. Cost-effectiveness ratios were estimated for RS-guided treatment compared with either tamoxifen alone or the combined chemotherapy and tamoxifen.

Results: Distant recurrence was reported in RS low-risk, intermediate-risk, and high-risk patients at 10 years in 3.7%, 17.8%, and 38.3% receiving tamoxifen alone and 5.0%, 10.1%, and 11.1% receiving the chemotherapy and tamoxifen. RS-guided therapy is associated with a gain in individual life expectancy of 2.2 years compared with tamoxifen alone, whereas it is associated with similar life expectancy to that seen with the chemotherapy and tamoxifen strategy. RS-guided therapy is estimated to provide a net cost savings of $2256 compared with chemotherapy and tamoxifen with an incremental cost-effectiveness ratio of $1944 per life year saved compared with tamoxifen alone.

Conclusions: Treatment decisions based on RS-guided therapy compared with tamoxifen alone are associated with greater efficacy with acceptable cost-effectiveness ratios, and associated with similar efficacy and lower cost compared with chemotherapy and tamoxifen for patients with lymph node-negative, estrogen receptor-positive early-stage breast cancer.

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med, 2009 Jan 07; 11(1). PMID: 19125125    Free PMC article.
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.
Daphne T Tsoi, Miho Inoue, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421264    Free PMC article.
Review of the clinical studies using the 21-gene assay.
Catherine M Kelly, Ellen Warner, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421266    Free PMC article.
Review.
Economics of cancer care.
Gary H Lyman.
J Oncol Pract, 2007 May 01; 3(3). PMID: 20859394    Free PMC article.
Editorial: gene expression profile assays as an aid in treatment decision making in early-stage breast cancer.
Gary H Lyman.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859408    Free PMC article.
Cost effectiveness of pharmacogenomics: a critical and systematic review.
William B Wong, Josh J Carlson, Rahber Thariani, David L Veenstra.
Pharmacoeconomics, 2010 Oct 13; 28(11). PMID: 20936884
Systematic Review.
Economic evaluation of targeted cancer interventions: critical review and recommendations.
Elena B Elkin, Deborah A Marshall, +4 authors, Kathryn A Phillips.
Genet Med, 2011 Jun 04; 13(10). PMID: 21637102    Free PMC article.
Review.
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.
Jennifer S Haas, Su-Ying Liang, +3 authors, Kathryn A Phillips.
Breast Cancer Res Treat, 2011 Jun 18; 130(2). PMID: 21681446    Free PMC article.
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
Ruth Oratz, Benjamin Kim, +4 authors, Michael Broder.
J Oncol Pract, 2011 Jul 07; 7(2). PMID: 21731516    Free PMC article.
Genomic testing and therapies for breast cancer in clinical practice.
Jennifer S Haas, Kathryn A Phillips, +5 authors, Michele Toscano.
J Oncol Pract, 2011 Sep 03; 7(3 Suppl). PMID: 21886507    Free PMC article.
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
John Hornberger, Rebecca Chien, Katie Krebs, Louis Hochheiser.
J Oncol Pract, 2011 Sep 03; 7(3 Suppl). PMID: 21886510    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Impact of multigene assays in early stage breast cancer.
Shelly S Lo, Kathy S Albain.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016475    Free PMC article.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
Jeffrey G Schneider, Danny N Khalil.
Breast Cancer Res Treat, 2012 Jun 23; 134(3). PMID: 22723033    Free PMC article.
The Nuremberg Code subverts human health and safety by requiring animal modeling.
Ray Greek, Annalea Pippus, Lawrence A Hansen.
BMC Med Ethics, 2012 Jul 10; 13. PMID: 22769234    Free PMC article.
Review.
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
Shelby D Reed, Michaela A Dinan, Kevin A Schulman, Gary H Lyman.
Genet Med, 2012 Sep 15; 15(3). PMID: 22975761    Free PMC article.
Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis.
Kuo Yao-Lung, Chen Dar-Ren, Chang Tsai-Wang.
BMC Med Inform Decis Mak, 2012 Sep 19; 12. PMID: 22985190    Free PMC article.
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
BMC Cancer, 2012 Oct 04; 12. PMID: 23031196    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, +13 authors, J Blohmer.
Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233    Free PMC article.
Citizens' perspectives on personalized medicine: a qualitative public deliberation study.
Yvonne Bombard, Julia Abelson, Dorina Simeonov, Francois-Pierre Gauvin.
Eur J Hum Genet, 2013 Jan 24; 21(11). PMID: 23340511    Free PMC article.
Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
Elizabeth Spellman, Nadiyah Sulayman, +4 authors, Suzanne C O'Neill.
Psychooncology, 2013 Mar 01; 22(9). PMID: 23447452    Free PMC article.
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
S Holt, G Bertelli, +12 authors, C J Phillips.
Br J Cancer, 2013 May 23; 108(11). PMID: 23695023    Free PMC article.
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.
Roman Rouzier, Paolo Pronzato, +3 authors, William J Valentine.
Breast Cancer Res Treat, 2013 Jun 01; 139(3). PMID: 23722312    Free PMC article.
Systematic Review.
Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
Pharmacoeconomics, 2013 Nov 30; 32(2). PMID: 24288208
The application of Oncotype DX in early-stage lymph-node-positive disease.
Sarika Jain, William J Gradishar.
Curr Oncol Rep, 2014 Jan 21; 16(1). PMID: 24442572
Review.
Oncotype dx results in multiple primary breast cancers.
Michael J Toole, Kelley M Kidwell, Catherine Van Poznak.
Breast Cancer (Auckl), 2014 Jan 24; 8. PMID: 24453493    Free PMC article.
Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.
Kimberly Mislick, Warren Schonfeld, Carolyn Bodnar, Kuo Bianchini Tong.
Clinicoecon Outcomes Res, 2014 Jan 29; 6. PMID: 24470765    Free PMC article.
Patients' perceptions of gene expression profiling in breast cancer treatment decisions.
Y Bombard, L Rozmovits, +3 authors, D A Marshall.
Curr Oncol, 2014 Apr 26; 21(2). PMID: 24764705    Free PMC article.
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Adam M Brufsky.
Am J Clin Oncol, 2014 May 24; 37(4). PMID: 24853663    Free PMC article.
Systematic Review.
Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment.
Y Bombard, L Rozmovits, +3 authors, D A Marshall.
Curr Oncol, 2014 Jun 19; 21(3). PMID: 24940102    Free PMC article.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.
N A Meadows, A Morrison, +2 authors, R W Barker.
Pharmacogenomics J, 2014 Oct 08; 15(1). PMID: 25287070
Review.
Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.
Michael Marrone, Alison Stewart, W David Dotson.
Genet Med, 2014 Dec 05; 17(7). PMID: 25474343    Free PMC article.
Review.
Can genomic medicine improve financial sustainability of health systems?
Christine Y Lu, Joshua P Cohen.
Mol Diagn Ther, 2015 Apr 12; 19(2). PMID: 25862552
Review.
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Joseph Gligorov, Xavier B Pivot, +11 authors, Francilian Breast Intergroup.
Oncologist, 2015 Jun 27; 20(8). PMID: 26112003    Free PMC article.
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Arnold L Potosky, Suzanne C O'Neill, +8 authors, Marc D Schwartz.
Cancer, 2015 Aug 21; 121(22). PMID: 26291519    Free PMC article.
Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
Lik Hang Lee, Paul E Swanson, +2 authors, Hua Yang.
Appl Immunohistochem Mol Morphol, 2015 Sep 16; 25(1). PMID: 26371428    Free PMC article.
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
J Natl Compr Canc Netw, 2015 Oct 21; 13(10). PMID: 26483061    Free PMC article.
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Megan C Roberts, Morris Weinberger, +5 authors, Stephanie B Wheeler.
J Clin Oncol, 2015 Nov 26; 34(2). PMID: 26598755    Free PMC article.
Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.
B Jahn, U Rochau, +7 authors, U Siebert.
Springerplus, 2015 Dec 23; 4. PMID: 26693110    Free PMC article.
Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
Chalanda N Evans, Noel T Brewer, +6 authors, Suzanne C O'Neill.
Breast Cancer Res Treat, 2016 Apr 10; 156(3). PMID: 27059031    Free PMC article.
Underutilization of gene expression profiling for early-stage breast cancer in California.
Rosemary D Cress, Yingjia S Chen, +2 authors, Kenneth W Kizer.
Cancer Causes Control, 2016 Apr 22; 27(6). PMID: 27097910    Free PMC article.
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.
Anosheh Afghahi, Maya Mathur, +14 authors, Allison W Kurian.
J Oncol Pract, 2016 May 26; 12(6). PMID: 27221993    Free PMC article.
Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Eun Young Chae, Woo Kyung Moon, +8 authors, Sei Hyun Ahn.
PLoS One, 2016 Jul 01; 11(6). PMID: 27362843    Free PMC article.
Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.
Marika Plöthner, Dana Ribbentrop, Jan-Phillipp Hartman, Martin Frank.
Adv Ther, 2016 Jul 14; 33(9). PMID: 27406232    Free PMC article.
Systematic Review.
Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.
Daniel M Trifiletti, Vanessa N Sturz, Timothy N Showalter, Jennifer M Lobo.
PLoS One, 2017 May 10; 12(5). PMID: 28486497    Free PMC article.
Systematic Review.
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
Govindasamy-Muralidharan Karthik, Mattias Rantalainen, +9 authors, Johan Hartman.
BMC Cancer, 2017 Dec 01; 17(1). PMID: 29187174    Free PMC article.
Cost Effectiveness of Gene Expression Profile Testing in Community Practice.
Young Chandler, Clyde B Schechter, +8 authors, Jeanne S Mandelblatt.
J Clin Oncol, 2018 Jan 09; 36(6). PMID: 29309250    Free PMC article.
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Shi-Yi Wang, Weixiong Dang, +3 authors, Cary P Gross.
J Clin Oncol, 2018 Apr 17; 36(16). PMID: 29659329    Free PMC article.
Systematic Review.
Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Jonathan Chen, Xian Wu, +2 authors, Himanshu Nagar.
Breast Cancer Res, 2018 Apr 18; 20(1). PMID: 29661221    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26.
Bradley M Turner, Mary Ann Gimenez-Sanders, +6 authors, David G Hicks.
Cancer Med, 2019 Jun 15; 8(9). PMID: 31199586    Free PMC article.
Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar.
Suzanne C O'Neill, Susan T Vadaparampil, +9 authors, Susan Eggly.
Patient Educ Couns, 2020 Sep 10; 104(2). PMID: 32900604    Free PMC article.
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Paolo Giorgi Rossi, Annette Lebeau, +13 authors, ECIBC Contributor Group.
Br J Cancer, 2021 Feb 19; 124(9). PMID: 33597715
Review.